ArticleJournal of physiology and biochemistry2026
Adipose-derived mesenchymal stem cells improved acute renal failure induced by ischemia-reperfusion injury: Focusing on toll-like receptor 4 activity and endoplasmic reticulum stress response.
Article in Journal of physiology and biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
This study evaluated the efficacy of adipose-derived mesenchymal stem cells (AD-MSCs) in reducing pathological alterations linked to acute kidney injury (AKI) caused by ischemia-reperfusion injury (IRI). In this study, 18 male rats were divided into three groups: Sham, IRI, and IRI + AD-MSC. IRI was induced by clamping the renal pedicles for 45 min, while the Sham group animals underwent the same surgical procedure without vascular clamping. In the IRI + AD-MSC groups, immediately after clamp removal, the animals received an intraperitoneal injection of 1 × 10⁶ AD-MSCs. To enable tracking, AD-MSCs were transfected with green fluorescent protein (GFP). The distribution of these labeled cells was examined at 24 and 48 h post-transplantation in three additional rats. Forty-eight hours after reperfusion, serum and kidney tissue samples were collected. The labeled AD-MSCs were more widely distributed in the injured kidney area of the IRI + AD-MSC group compared to the control group. In the group treated with AD-MSCs, there were notable reductions in serum blood urea nitrogen (BUN) and creatinine levels (P < 0.001), along with improvements in renal tissue damage and oxidative stress (P < 0.01). Additionally, the IRI + AD-MSC group showed significant decreases in toll-like receptor-4 (TLR4) protein levels (P < 0.01) and pro-inflammatory factors (P < 0.001), as well as reduced levels of endoplasmic reticulum (ER) stress proteins compared to the IRI group. This study suggested that AD-MSCs administration alleviates AKI, possibly by modulating TLR4 activity, decreasing inflammation, and reducing ER stress.
Indexed as
Identifiers
42435285What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.